FY2027 1Q Earnings Presentation
Filed with TSE · · 12 pages · English
Summary by 6ix AI
The report highlights a decrease in consolidated net sales and EBITDA compared to the previous year, although both figures exceeded management expectations. Despite challenges such as lower revenue and rising costs, the company reported significant improvements in cash flows from operations and plans to acquire treasury stock to enhance shareholder value. Additionally, Daito has made progress in its strategic initiatives, including a share transfer agreement to strengthen its position in the pharmaceutical market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Daito Pharmaceutical Co., Ltd. on 6ix
In the deck
Story so far
Earlier from Daito Pharmaceutical
- Execution of JV and Share Transfer Agreement for Transfer of KYORIN Pharmaceutical's Generic Drug Business to JV by Daito, Meiji Seika Pharma and DBJ
- FY2026 4Q Earnings Presentation
- Notice Regarding the Results and Completion of the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNet-3)
- Summary of Consolidated Financial Results for the Fiscal Year Ended May 31,2026 (Under Japanese GAAP)
- Summary of Consolidated Financial Results for the Six Months Ended November 30, 2025 (Under Japanese GAAP)
Later from Daito Pharmaceutical
All Daito Pharmaceutical news releasesFollow Daito Pharmaceutical into a list and get an email when it puts out news.
Follow Daito Pharmaceutical